来源：新浪基金∞工作室 2月24日，万家中证港股通央企红利ETF（159333）收盘涨2.49%，成交额2882.40万元。 港股央企红利ETF万家（159333）成立于2024年8月21日，基金全称为万家中证港股通央企红利交易型 开放式指数证券投资基金，基金简称为万家中证港股通央企红利ETF。该基金管理费率每年0.50%，托 管费率每年0.10%。港股央企红利ETF万家（159333）业绩比较基准为中证港股通央企红利指数收益率 (经估值汇率调整)。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 流动性方面，截止2月24日，港股央企红利ETF万家（159333）近20个交易日累计成交金额3.82亿元， 日均成交金额1909.48万元；今年以来，31个交易日，累计成交金额5.78亿元，日均成交金额1863.49万 元。 港股央企红利ETF万家（159333）现任基金经理为杨坤。杨坤自2024年8月21日管理（或拟管理）该基 金，任职期 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 三愛健康産業集團有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01889 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 三愛健康産業集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01889 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底 ...

Fund Allocation - The company plans to allocate approximately 45% of the net proceeds from the issuance of convertible bonds for the purchase of production facilities, equipment, and raw materials for pharmaceutical products [2]. - About 30% of the net proceeds will be used to enrich the pharmaceutical product base, including the development of new drugs and/or obtaining drug licenses [2]. - Approximately 25% of the net proceeds will be allocated to increase sales points and additional sales personnel costs [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 三愛健康産業集團有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01889 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月 ...

Core Viewpoint - Sanai Health Group (01889) has entered into a share transfer agreement to sell 99% of its equity in Luan Nan Hang Yang Health Industry Co., Ltd. for approximately RMB 18.69 million, which will be settled in cash [1][2] Group 1 - The seller, Beijing Hang Yang Health Technology Co., Ltd., a non-wholly owned subsidiary of the company, has agreed to sell its stake in the target company [1] - The target company, established in January 2018, has not commenced operations and holds a land parcel of approximately 67,000 square meters in Luan Nan, China [1] - The board believes that continuing to hold the stake may not yield the best returns for shareholders, and the sale is seen as an ideal opportunity to generate additional cash flow [1] Group 2 - The estimated net proceeds from the sale, after deducting related expenses, are approximately RMB 18.68 million, which the company plans to use for general working capital and other business development [2] - The completion of the sale is expected to improve the group's liquidity position and strengthen its financial status, allowing the company to focus on its core business [2]

Core Viewpoint - Sanai Health Group (01889) has entered into a share transfer agreement to sell 99% of its subsidiary, Luan Nan Hang Yang Health Industry Co., Ltd., for approximately RMB 18.69 million, aiming to enhance cash flow and focus on core business areas [1][2] Group 1: Sale Agreement Details - The seller, Beijing Hang Yang Health Technology Co., Ltd., a non-wholly owned subsidiary, has agreed to sell the shares to buyer Xue Wenfen for about RMB 18.69 million, to be settled in cash [1] - The target company, Luan Nan Hang Yang Health Industry Co., Ltd., is an indirect non-wholly owned subsidiary that has not commenced operations since its establishment in January 2018 and holds a land parcel of approximately 67,000 square meters in Luan Nan, China [1] Group 2: Financial Implications - The estimated net proceeds from the sale, after deducting related expenses, are approximately RMB 18.68 million, which the company plans to use for general working capital and other business development [2] - The completion of the sale is expected to improve the group's liquidity and strengthen its financial position, allowing the company to concentrate on its core business [2]

Core Viewpoint - Sanai Health Group (01889.HK) has announced the sale of a 99% stake in its subsidiary, Luanan Hangyang Health Industry Co., Ltd., for approximately RMB 18.69 million, which will be settled in cash. The decision to sell is driven by unfavorable market conditions and aims to enhance cash flow and focus on core business areas [1][1][1] Group 1 - The seller, Beijing Hangyang Health Technology Co., Ltd., is a non-wholly owned subsidiary of the company [1] - The target company has not commenced actual operations and was initially intended to build production facilities to expand health product capacity [1] - The management has decided to terminate the expansion plan due to recent adverse market conditions [1] Group 2 - The board believes that continuing to hold the stake in the target company may not yield the best returns for shareholders [1] - The sale is seen as an ideal opportunity to create additional cash flow for the company [1] - The net proceeds from the sale, estimated at approximately RMB 18.68 million after related expenses, will be used for general working capital and other business development [1] Group 3 - The completion of the sale is expected to improve the group's liquidity position and strengthen its financial status [1] - The divestment will allow the group to streamline operations and reallocate resources to areas with stronger competitive advantages and expertise [1]

Core Viewpoint - Sanai Health Group (01889.HK) has announced the sale of a 99% stake in its subsidiary, Luanan Hangyang Health Industry Co., Ltd., for approximately RMB 18.69 million, to improve cash flow and focus on core business areas [1] Group 1: Sale Agreement Details - The seller, Beijing Hangyang Health Technology Co., Ltd., a non-wholly owned subsidiary, has entered into an agreement with buyer Xue Wenfen for the sale [1] - The transaction will be settled in cash, with the target company not having commenced actual operations [1] - The original plan for the target company was to build production facilities to expand health product capacity, but this plan has been terminated due to unfavorable market conditions [1] Group 2: Financial Implications - The board believes that holding onto the target company's equity may not yield the best returns for shareholders [1] - The net proceeds from the sale, estimated at approximately RMB 18.68 million after related expenses, will be used for general working capital and other business development [1] - The completion of the sale is expected to improve the group's liquidity and strengthen its financial position, allowing it to focus on areas with stronger competitive advantages [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sanai Health Industry Group Company Limited 三愛健康產業集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1889） 須予披露交易 該協議之主要條款概述如下。 – 1 – 出售附屬公司 該協議 董事會欣然宣佈，於二零二五年十一月十日（於聯交所交易時段後），賣方（本公司 之一間非全資附屬公司）與買方就出售事項訂立該協議，據此，賣方已同意出售， 而買方已同意購買股權，代價為約人民幣18.69百萬元並將以現金結算。 上市規則之涵義 由於根據上市規則第14.06條計算有關出售事項的最高適用百分比率超過5%但低 於25%，故根據上市規則第14章，出售事項構成本公司的須予披露交易。出售事 項須遵守上市規則第14章項下的申報及公告規定，惟獲豁免遵守股東批准規定。 緒言 董事會欣然宣佈，於二零二五年十一月十日（於聯交所交易時段後），賣方（本公司 之一間非全資附屬公司） ...